Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
About Amphastar:
Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.
The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST®, Amphadase®, Cortrosyn®, REXTOVY® and BAQSIMI® are the property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expect,' 'intend,' 'plan,' 'project,' 'believe,' 'estimate,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients with stable disease. Based on this promising data, BioInvent plans to initiate Phase 2a expansion cohorts to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) or uveal melanoma, in the front line in combination with KEYTRUDA® (pembrolizumab). Patient enrollment is expected to begin H2 2025. LUND, SE / / June 11, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated, positive Phase 1 data of intravenous (IV) and subcutaneous (SC) BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors. Based on the encouraging data, the company intends to expand its investigation of BI-1206 SC in combination with pembrolizumab in earlier lines of treatment, by initiating a Phase 2a study arm with focus on first-line patients with advanced or metastatic NSCLC and uveal melanoma. The Phase 2a study is planned to be initiated during H2 2025. The updated Phase 1 data in heavily pre-treated patients - including several lines of IO agents - show encouraging clinical activity of the combination, with one patient with metastatic cutaneous melanoma experiencing a complete response (CR), one patient with metastatic uveal melanoma achieving a long-lasting partial response (PR) and 11 patients experiencing stable disease (SD) out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. The trial is part of BioInvent's strategy to transition from IV dosing to SC formulation for BI-1206 allowing slower systemic entry and prolonged time on target to enhance the products therapeutic impact and improve safety and tolerability of the combination. The Phase 1 data in solid tumors corroborate preclinical findings that BI-1206 significantly enhances the effect of anti-PD-1. Based on this evidence, MSD and BioInvent have agreed to further investigate the synergies between BI-1206 and pembrolizumab in earlier lines of treatment. The upcoming Phase 2a study of BI-1206 in combination with pembrolizumab is planned to be performed in treatment-naïve patients with NSCLC and uveal melanoma. "We are highly encouraged by the clinical responses emerging from our solid tumor program which support the broad utility of combining subcutaneous BI-1206 with pembrolizumab in a range of solid tumors," said Martin Welschof, Chief Executive Officer of BioInvent. "The strong signals we have observed in heavily pre-treated patients support the idea that BI-1206 could be used to improve the activity of pembrolizumab across different tumor types, and we therefore look forward to initiating our Phase 2a study in the high unmet medical need of non-small cell lung cancer." KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ###About NSCLC and combination treatment with targeting FcyRIIBNSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. While checkpoint inhibitors are widely accepted and can produce durable responses in NSCLC, the overall response rate remains low, rarely exceeding 25%. A common resistance mechanism in cancer is the binding and degradation of therapeutic antibodies against PD-1 such as pembrolizumab by FcγRIIB expressing immune cells. Therefore, based on preclinical and early clinical data, the company believes that resistance or lack of response to anti-PD-1 treatment may be overcome by FcγRIIB blockade in particular in subjects who have never been exposed to anti PD-1 agents. About BI-1206BI-1206 is one of BioInvent's lead drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab. The drug candidate is evaluated in two separate clinical programs, one for the treatment of solid tumors and one for the treatment of non-Hodgkin's lymphoma (NHL, a type of blood cancer). BI-1206 in solid tumorsClinical Phase 1/2a study with BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors (NCT04219254) is ongoing. The concluded Phase 1 dose escalation study in heavily pre-treated patients shows encouraging clinical activity of the combination, including one CR in metastatic melanoma, one PR in uveal melanoma and 11 patients experiencing SD out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. For further details, please refer to the ASCO 2024 poster on the company web site: Out of the patients with stable disease as best response, one patient with long-lasting metastatic melanoma, who had previously progressed on nivolumab treatment, remained a stable disease throughout the two-year study duration with BI-1206 and pembrolizumab. The planned Phase 2a study of BI-1206 in combination with pembrolizumab for treatment-naïve patients with NSCLC and uveal melanoma consists of two parts: a signal seeking phase and a dose optimization phase. In the first signal seeking phase, up to 30 NSCLC and 12 uveal melanoma patients will receive fixed doses of BI-1206 and pembrolizumab every 21 days for three treatment cycles. Patients showing clinical benefit by Week 9 can continue therapy for up to 32 additional cycles, while those with disease progression will not proceed further. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. Attachments BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors SOURCE: BioInvent International View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
36 minutes ago
- Yahoo
eSIM Go and CSG Accelerate, Simplify MVNO Journey
Modernised platform streamlines onboarding, enhances user experience and powers agile growth for MVNO customers LONDON, June 11, 2025--(BUSINESS WIRE)--As the global mobile virtual network operator (MVNO) market surges towards a projected $137 billion by 2030, eSIM Go, a digital connectivity pioneer, is scaling for future growth. With its modernised user platform, developed in collaboration with CSG® (NASDAQ: CSGS), eSIM Go will simplify and speed up the MVNO journey, enabling faster onboarding, richer self-service and seamless integration of digital offerings. "Businesses from fintechs to airlines are looking to deepen customer relationships by offering custom digital mobile services. But becoming an MVNO has traditionally been a slow, complex and inflexible process," said Zacc Couldrick, CEO, eSIM Go. "As we aim to eliminate the barriers to entry into the digital connectivity space, we needed a technology provider with deep network relationships and a history of simplifying complex processes. With CSG's proven, cloud-native technology, we've built a platform that makes it easy to launch, integrate and personalise connectivity offerings that customers truly value." eSIM Go's next-generation platform allows businesses to deploy new wireless services in as little as 48 hours. By integrating CSG Ascendon into the platform, eSIM Go customers benefit from streamlined onboarding and offboarding, and a fast, intuitive self-service experience. Whether scaling a product portfolio or entering new markets, eSIM Go customers can move with greater speed and agility to meet the evolving demands of a digital economy. "We're seeing a resurgence in MVNO innovation, as businesses create tailored connectivity services for niche and underserved markets," said Sean Casey, SVP, Product Management, CSG. "In a complex partnership ecosystem, eSIM Go's modernised platform redefines what's possible, making MVNO onboarding faster, easier and more scalable while building loyalty that lasts. This is a pivotal step in the evolution of digital connectivity, and it's an honour for CSG to support eSIM Go as it leads the charge in delivering simplified, future-ready solutions for sustainable growth." Discover how CSG's cloud-native platform supports innovation and scalability for MVNOs and for MVNEs, helping innovators like Three Group Solutions drive agility and growth. About CSG CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world. Want to be future-ready and a change-maker like the global brands that trust CSG? Visit to learn more. About eSIM Go eSIM Go empowers businesses of any size to offer their own digital connectivity solutions to customers, providing everything needed to scale their global opportunity and go to market fast. Any commercial model can be aligned with eSIM Go's complete eSIM product ecosystem, enabling business partners to embed our capabilities into their product via API, co-brand a fully managed eSIM service or pursue an affiliate route. Global brands in travel, MNO/MVNO, fintech and more trust eSIM Go to generate revenue and increase customer loyalty through high quality eSIM data bundles based on over 1,000 networks in 190+ countries. For more, see View source version on Contacts Julia DakhliaPublic Relations+1 (402) John ReaInvestor Relations+1 (210) Davis BarkerInvestor Relations+1 (303) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Which Software Stocks Is BofA Securities Bullish On?
The BofA Securities software research team hosted 18 public and 10 private companies at the BofA Global Technology Conference in San Francisco on June 3-5. With an ever-changing macro policy backdrop, the spending environment was the focus of this discussion. AI product cycles were another key topic discussed, with companies citing healthy pilot activity for agentic applications. Based on discussions, participating software companies endorsed a generally stable environment, although companies remained cognizant of underlying the analyst report noted that while product cycles for agentic AI are still in their early stages, they are reportedly gaining traction through initial pilot deals. Analyst Brad Sills included key takeaways from meetings with participating companies in this report. Sills said Microsoft Corp.'s (NASDAQ:MSFT) (Buy, price forecast $515) Commercial CFO Mat McBride suggested sustained momentum in the Azure business, led by healthy cloud migration. According to the analyst, Microsoft is rapidly innovating across the enterprise stack. ServiceNow's (NYSE:NOW) (Buy, price forecast $1,085) Chief Customer Officer Chris Bedi highlighted solid execution through a tough macro environment in the tariff-impacted manufacturing vertical and DOGE-impacted Federal vertical. ServiceNow noted sustained momentum across the broad IT, customer, and employee application suites. It is expanding rapidly to multiple departments in the enterprise. In front office applications, Salesforce's (NYSE:CRM) (Buy, price forecast $350) COO and CFO, Robin Washington, reiterated pockets of weakness in tariff-impacted verticals like manufacturing and retail, though noting strength elsewhere, Sills said. According to the analyst, Salesforce is driving growth in both core and Agentforce. The analyst noted that Datadog's (NASDAQ:DDOG) (Buy, price forecast $138) CFO, David Obstler, highlighted the company's expanding product offering and its long-term growth potential for monitoring cloud workloads, which are increasing in volume and complexity due to AI. The analyst noted that Datadog's AI-native cohort is growing quickly, though volatility is inherent in the consumption model. Sills said Asana (NYSE:ASAN) (Buy, price forecast $21) noted slight incremental macro headwinds in April for its enterprise segment. According to the analyst, AI Studio could represent a powerful second-half 2026 catalyst for Asana. The analyst noted that software firms cited solid leading indicators for agentic application adoption, though these cycles remain nascent. He said data management vendors such as Microsoft noted added database activity as enterprises prepare for running agentic AI applications. DevSecOps software vendor JFrog (NASDAQ:FROG) (Buy, price forecast $48) discussed how AI-focused code is beginning to show up more this year, Sills said. The analyst pronounced JFrog's setup good heading into the second half of 2025. Application vendors Salesforce and ServiceNow cited healthy pilot activity for agentic applications, Agentforce, and Now Assist, the analyst noted. However, he said revenue targets are limited at this cycle stage. Microsoft cited hundreds of thousands of customers running Microsoft 365 Copilot, expanding deployments, Sills noted. He said that OneStream (NASDAQ:OS) (Buy, price forecast $33) highlighted its attractive AI value proposition and adoption trends in the back office with its SensibleAI Forecast offering. OneStream is an AI-powered back-office disruptor. The analyst said Asana and Freshworks (NASDAQ:FRSH) (Neutral, price forecast $18) noted healthy demand for AI Studio and Freddy AI. Freshworks' AI offerings are driving up the list across all growth levers. Read Next:Photo by Bumble Dee via Shutterstock Date Firm Action From To Feb 2022 Tigress Financial Maintains Buy Jan 2022 Citigroup Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for MSFT View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MICROSOFT (MSFT): Free Stock Analysis Report SALESFORCE (CRM): Free Stock Analysis Report SERVICENOW (NOW): Free Stock Analysis Report FRESHWORKS (FRSH): Free Stock Analysis Report This article Which Software Stocks Is BofA Securities Bullish On? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
